Abstract Spinal muscular atrophy is an autosomal recessive neuromuscular disease mainly caused by homozygous deletion of SMN1. The 2-copy SMN1 allele may present in the families of SMA patients with homozygous deletion of SMN1, one of whose parents has two SMN1 copies. In such families, individuals having two SMN1 copies still have a chance to be B2 + 0^carriers. In this study, the risks for the parents, fetuses and other siblings having two SMN1 copies to be B2 + 0^carriers were estimated based on Chinese metaanalysis data and turned out to be rather striking. Our findings would help to optimize genetic counseling regarding spinal muscular atrophy.
Introduction
Spinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases causing infant mortality, with an incidence of about 1 in 10000 births (Pearn 1980) . SMA is characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. More than 98 % of patients with spinal muscular atrophy have a homozygous disruption of the Survival of Motor Neuron 1 (SMN1) gene by deletion, rearrangement, or mutation (Lefebvre et al. 1995; Pearn 1980) . The SMN genes are located in a reverse duplication region on 5q13.2, representing in multiple copies: one SMN1 (SMNt, telomeric) and several SMN2 (SMNc, centromeric). The coding regions of these two genes differ in only one base (Burglen et al. 1996) . SMN2 presents an 840C > T transition in exon 7, which causes 90 % of its spliced isoform with no exon 7, generating a nonfunctional SMN protein (Lefebvre et al. 1995) . The instability of the 5q13 region leads to a great diversity of genotypes and a high de novo mutation rate (Wirth et al. 1997) . In addition to fragment deletions, a C-to-T conversion of the position 6 of exon 7 would also lead to the copy number loss of SMN1 (Burghes 1997) . Through screening in normal individuals, three copies of SMN1 have been identified in normal individuals, implying the presence of two SMN1 copies on a single chromosome 5 (Chen et al. 1999; McAndrew et al. 1997) .
For SMA patients and families, genetic diagnosis and carrier testing have already been implemented in clinics. In some SMA families, the patients were found to have SMN1 homozygous deletion, but two copies of SMN1 were detected in one of their parents (B2 copies^parent for short). Possible explanations are as follows: 1) the B2 copies^parent is a B2 + 0^carrier (two SMN1 copies on one chromosome and zero copies on the other chromosome); 2) the B2 copies^parent is a carrier with germline mosaicism; 3) the parent is normal but the patient has a de novo deletion. If the first explanation is the actual situation, the B2 copies^parent and all the B2 copies^siblings of the patient would be B2 + 0^SMA carriers, who should be made aware of the possible recurrence of SMA in their offspring and available preventive measures such as carrier testing and prenatal diagnosis. Even though prenatal diagnosis identified an unaffected fetus with two SMN1 copies, it would still be a B2 + 0^carrier. In order to discriminate B2 + 0^carriers from B1 + 1^unaffected individuals, linkage analysis or monoclonal testing must be performed in addition to regular SMN1 dosage assay. However, the analysis is rarely applied in clinical services because of the limits in samples, time and technique. If a confirmation of carrier status is absent, a reliable estimate of the carrier risks of the B2 copies^parents, fetuses and other siblings based on statistical data would be very meaningful for genetic counselors in order to remind the B2 copies^SMA families of the potential recurrence of SMA and to highlight the availability of prenatal diagnosis for the next generation.
The frequency of the SMN1 2-copy allele and the proportion of B2 copies^parents are indispensable for the investigation of carrier risks. In 2004, Ogino et al. published a reliable meta-analysis method which they used to calculate the SMN1 allele frequencies in a population of mixed ethnicities (Ogino et al. 2004 ). However, evidence provided by Hendrickson et al. (2009) showed significant differences between SMN1 allele frequencies of ethnic groups. Unfortunately, the sample sizes of each ethnic group in this study were limited to around 1000, and thus large-scale and ethnicity-specific data regarding SMN1 allele frequencies are still lacking. On the other hand, Alías et al. (2014) recently reported the proportion of B2 + 0^genotype in SMA carriers at 2~5 % based on genetic testing results. Nevertheless, the proportion of parents with two copies of SMN1 has not yet been explored.
In the present study, carrier risks for individuals having two copies of SMN1 in SMA families with 2-copy alleles were deduced. We performed a meta-analysis including large sample sizes from the Chinese population in order to generate a solid data basis for this calculation.
Methods

Literature Search
On 15 April 2015, Pubmed, Embase, Cochrane library, Database of Chinese Scientific and Technical Periodicals (VIP), China National Knowledge Infrastructure for relevant studies published in English or Chinese (CNKI), Wanfang and Sinomed were systematically searched using the following search terms: BChinese^plus Bspinal muscular atrophy^or BSMN1^or Bgenetic^or Bmolecular^, combined with Bpopulation^or Bscreening^or Bdiagnosis^or Bepidemiology^. Chinese databases were searched in Chinese. All search results were imported into NoteExpress2 software to remove duplication.
Study Selection
We selected informative studies through a two-step selection process. The first-step aimed to include literatures which would contain required data as comprehensively as possible and exclude inappropriate studies. The inclusion or exclusion decisions about each study were made by reading the title and abstract. The full text would also be reviewed if information contained in the title and abstract was not sufficient.
The inclusion criteria were: 1) samples of Chinese living in China (including Hong Kong and Taiwan); 2) SMN1 gene dosage assay was performed.
The exclusion criteria were: 1) Chinese out of China; 2) meeting abstracts, case reports, editorials, newsletters and review articles; 3) when the same researchers conducted multiple studies, in which specific gene copy numbers for the same samples may be repeatedly reported, we excluded the publications in which data appeared to already be included in the other paper(s).
After the first-step selection, full articles of all included literatures were obtained and reviewed. Then, studies went through a second-step selection. They were classified into three categories based on test population. One study may be classified into multiple categories. For each category, the inclusion criteria were as 'follows:
Category A: 1) random sampling from normal people, either research subjects or controls; 2) sample size no smaller than thirty; 3) reporting the numbers of individuals detected with 1, 2, 3 or 4 copies of SMN1. Category B: 1) random sampling from clinically diagnosed SMA patients; 2) sample size no smaller than ten; 3) patients with SMN1 heterozygous deletion could be detected by the applied methods; 4) reporting the numbers of patients detected with 0, 1 or 2 copies of SMN1. Category C: 1) genetic testing had been performed on parents of the patients with SMN1 homozygous deletion; 2) reporting the numbers of such parents detected with 1 or 2 copies of SMN1.
We excluded some earlier studies, in which heterozygous deletions were identified by lighter shade of the PCR-RFLP electrophoretic bands, because of the unreliability of this method.
Data Extraction
Data gathered from each eligible study included: author, sample sources, sampling time, and gene testing technologies. For each category, particular requirements are as follows:
Category A: 1) sample size; 2) numbers of people who were detected to have 1, 2, 3 and 4 copies of SMN1. Category B: 1) the number of tested patients; 2) numbers of patients who were detected to have 0, 1 or 2 copies of SMN1. Category C: 1) the number of tested parents; 2) numbers of parents who were detected to have 1 or 2 copies of SMN1.
The process of study selection and data extraction was conducted independently by two work groups. Pu Yang and Rui Zhang composed Group A, and Bo Tan and Yue Zhang composed Group B. Discrepancies between the two groups were discussed by all individuals. If consensus was not reached, Group C, composed of Xianda Wei and Hu Tan, would make a final decision.
Data Analysis
For each category, data extracted from selected studies were pooled together. Genotype frequencies were then calculated. We defined four kinds of SMN1 alleles as: 0-copy alleles and 1 D alleles (one gene copy with a point mutation) that are disease-causing, 1-copy alleles and 2-copy alleles that are normal. We calculated allele frequencies using genotype frequencies in Category A and Category B, applying the methods reported by Ogino et al. (2004) . Based on data in Category C and allele frequencies, we estimated carrier risk of B2 copies^parents and further deduced carrier risk of B2 copiesŝ iblings following Bayes' theorem. Data analysis was performed independently by Group A, Group B and Group C. Discrepancies among the three groups were further discussed by all individuals to reach consensus.
Results
Figure 1 illustrates the selection process for studies included in the meta-analysis. A total of 928 studies were identified through the initial literature search. After the first-step selection, we reviewed 98 papers in full. After the second-step selection, eligible studies in each category were determined.
Category A The numbers of normal people with different genotypes were extracted from 18 studies and pooled together as shown in Table 1 . We designated the allele frequencies as: a = 0-copy allele frequency, b = 1-copy allele frequency, c = 2-copy allele frequency, d = 1 D allele frequency. Assuming Hardy-Weinberg equilibrium,
Because a, c and d are small, assume 2 ac = 2bd = 2 cd = 0 Then, from (3), b = 0.950.
From (2) and (4), a = 0.0111, c = 0.0388, and 2 ac = 0.000861.
Putting back into (3), we received b = 0.950 again. So, the allele frequencies after reiterative calculation would be a = 0.0111, b = 0.950, c = 0.0388. Category B The numbers of SMA patients with different genotypes were extracted from 10 studies and pooled together as in Table 2 . For the calculation of 1 D allele frequency, a fraction of individuals who were detected to have one 0-copy allele and one 1 D allele in all SMA patients is needed. However, no such data are available in the Chinese population so far. Wirth et al. (1999) reported that all in 17 SMA patients with heterozygous deletion of SMN1 exon 7 were detected to have intragenic mutations on the only SMN1 allele by sequencing cloned reverse-transcription (RT) PCR products or genomic fragments of SMN1. Thus, in order to make an approximate estimate of d, we can assume that each of the 58 heterozygous patients carries a 1 D allele. Thus:
. . Category C The numbers of parents with different genotypes were extracted from 20 studies and pooled together as in Table 3 . In the total 812 healthy parents of SMA patients with homozygous deletion of SMN1, 759 (93.47 %) were detected to be B1 + 0^carriers, and 53 (6.53 %) have two copies of SMN1, who may be SMA carriers or normal people. Theoretically, in any group of people from a general population, the ratio between the number of B2 + 0Ŝ MA carriers and the number of B1 + 0^SMA carriers can be estimated by 2 ac/2ab = c/b, which, in our study, would be 0.0409. Thus, when 759 B1 + 0^carriers were identified, there shall be 759*0.0409 ≈ 31 B2 + 0^carriers were also identified. So, in the 53 B2 copies^parents under carrier testing, we can expect 31 (58.49 %) to be B2 + 0ĉ arriers and 22(41.51 %) of them to be B1 + 1^unaffected people, for germline mosaicism is rare (approximately 1 %) (Alías et al. 2014) .
Because the possibility for two B2 copies^parents in the same SMA family is low, we assume that all the spouses of B2 copies^parents were B1 + 0^carriers. According to the Law of Segregation, a B2 + 0^carrier and a B1 + 0^carrier have a 1/4 chance to have a child with two SMN1 copies, who must be a B2 + 0^carrier. A B1 + 1^normal person and a B1 + 0^carrier have a 1/2 chance to have a child with two SMN1 copies, who must be a B1 + 1^normal person. So, the risk for a B2 copies^fetus to be a B2 + 0^SMA carrier can be estimated at 58.49 % * 0.25 / (58.49 % * 0.25 + 41.51 % * 0.5) ≈ 41.33 %. It would be same for the other siblings of B0 copy^SMA patients. 
Discussion Practice Implications
Technical standards and guidelines for spinal muscular atrophy testing established by the American College of Medical Genetics involve cautions regarding residual carrier risks following identification of two copies of SMN1 exon 7 and stress the importance of optimized risk assessment calculations using Bayesian analysis for the proper genetic counseling of SMA families (Prior et al. 2011 ). However, methods for estimating risk and examples of such risk estimation have rarely been reported. Our study illustrates that about 13 % (53/812*2) of the Chinese SMA patients with homozygous deletion of SMN1 would have one parent as a B1 + 0^carrier and another parent with 2 SMN1 copies, whose risk to be a B2 + 0^SMA carrier was estimated at 58 %. Even if an unaffected fetus with two SMN1 copies was identified through prenatal testing and was finally born, there is still a 41 % risk for him/her to be B2 + 0^carrier, the same as all the other children of the parents. It can be seen that, neither the 13 % proportion of these cases nor the 41 % carrier risk can be regarded as small numbers. Clinicians and genetic counselors should be aware of the possibility of B2 copies^events, which means offering carrier testing to the parents of patients with SMN1 homozygous deletion, instead of directly testing the fetuses regardless of the risk to be carriers. Timely informing about the carrier risk in prenatal genetic counseling would keep the B2 copiesŜ MA families alerted to the recurrence of SMA in the next generation, and offer them the options of carrier testing and prenatal diagnosis. Linkage analysis or monoclonal testing to discriminate B2 + 0^from B1 + 1^genotype should be recommended under suitable conditions.
For ethnic groups other than Chinese, these carrier risks may be even higher. According to the results of a study by Hendrickson et al. (2009) (Table 4) , both Ashkenazi Jewish and Hispanic individuals present higher c/b values than Chinese, indicating larger likelihood for B2 copies^individ-uals to have 2-copy alleles. Remarkably, this value reached up to 0.374 for African Americans, which is nearly ten times as much as that for Chinese, highlighting the great need to attend to the carrier risks of individuals having multiple SMN1 copies and specific genetic counseling in the African population. In order to calculate a risk estimation in any populations, our methods can be applied.
Study Limitations and Research Recommendations
It is important to note several limitations of this study: (1) Despite eliminating obvious duplications of published data, we may have overestimated the proportion of B2 copies^fam-ilies by repeatedly counting samples. This possibility cannot be excluded because of the lack of patient information reported in the original articles. (2) China is a country with a wide geographic area and multiple nationalities. We were not able to make nationality-specific calculations as data about single nationality were lacking. (3) In Category A, most of the included studies are from Southern China rather than the North. Moreover, we included 107611 samples from a study in Taiwan, which comprises 90.64 % of the total samples. Thus, unavoidable bias was created toward the Southern Chinese population. (4) Multiple techniques to determine SMN1 copy numbers were applied in SMA genetic studies Gu ( including MLPA, Quantitative PCR and DHPLC, with higher or lower sensitivities. (5) Publication bias may be caused by some publications in Category A reporting carrier incidences that were falsified to approach a well-accepted value. Some publications in Category B may hide patients detected with one or more SMN1 copies for higher accurate diagnosis rates of SMA, which would make the 1 D allele frequency calculated in our study lower than its actual value. (6) Finally, a recognized limitation of meta-analyses is the overreliance on published data, which are often biased toward statistically significant findings. Thus, conclusions based upon the results of the present study should be made with caution. Additional analyses that include unpublished data will help to validate the findings of the current study.
Conclusion
Our estimation of the carrier risks for the parents, fetuses and other siblings in SMA families with 2-copy alleles is based on large-scale and ethnicity-specific data. We call for clinicians to provide optimized genetic counseling and options of preventive measures to individuals who have notable carrier risks.
